Trial Profile
A Phase II, Open-label Study to Evaluate the Effect of Blinatumomab Administered During Consolidation to Reduce the Level of Minimal Residual Disease (MRD) Assessed Through Flow Cytometry in Adult Patients up to 55 Years of Age With High-risk Philadelphia Chromosome-negative (Ph-) Acute Lymphoblastic Leukaemia (ALL) With Good Response (MRD < 0.1%) After Induction Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2022
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms BLIN-01
- 26 Jul 2022 Status changed from suspended to discontinued.
- 21 Jul 2022 Status changed from active, no longer recruiting to suspended due to low rate of recruitment.
- 14 Apr 2021 Status changed from recruiting to active, no longer recruiting.